Clinical trials
Relapsed or Refractory Peripheral T Cell Lymphoma clinical trials
Below are recruiting relapsed or refractory peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,697 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT02917083RecruitingPhase 1
CD30 CAR T cell treatment for hard-to-treat lymphomas
This Phase 1 trial tests a new immune therapy made from your own immune cells (CAR T cells) for relapsed or refractory Hodgkin or non-Hodgkin lymphoma that has CD30 on the tumor. It aims to see if the treatment can shrink the lymphoma and find the safest dose.
Houston, TexasAges 12–75 - NCT06287528RecruitingPhase 1
CAR T‑cell therapy with IL‑18 for returning B‑cell leukemia
This trial tests a new type of CAR T‑cell therapy that also makes an immune‑boosting protein called IL‑18. It is for people with B‑cell acute lymphoblastic leukemia that has come back or not gone away after standard treatments.
Basking Ridge, New JerseyAges 17 years+ - NCT05848765RecruitingPhase 2
Trial for relapsed follicular lymphoma after prior chemo
This Phase 2 trial studies treatment options for follicular lymphoma that has returned or did not respond to prior therapy. It compares a standard chemotherapy approach against another study treatment to see which works better and is tolerable.
AberdeenAges 18 years+ - NCT07082868RecruitingPhase 1
Study of epcoritamab and ibrutinib for central nervous system lymphoma
This trial tests a combination of two drugs, epcoritamab and ibrutinib, for people whose lymphoma has come back or not responded to treatment and has spread to the brain or spinal cord. The goal is to see if this combination can help control the disease.
Basking Ridge, New JerseyAges 18 years+ - NCT07070323RecruitingPhase 1/Phase 2
Nanobody CD5-CAR T cells for T-cell cancers
This trial tests a new treatment using your own or a donor's immune cells to fight certain T-cell cancers that haven't responded to standard therapies. It may help people who have few other options left.
Beijing, Beijing MunicipalityAges 1–70 - NCT07672483RecruitingPhase 1
Gene therapy for solid tumors that returned after treatment
This trial tests a new type of gene therapy that uses your own immune cells (called myeloid cells) engineered to produce a protein (IL-12) to fight your cancer. It is for people with solid tumors that have not responded to standard treatments.
Bethesda, MarylandAges 18–120 - NCT05562024RecruitingPhase 1
Study drug for B7-H3 positive neuroblastoma after relapse
This Phase 1 study tests TAA06, an injection that targets a marker called B7-H3 on neuroblastoma tumor cells. It is for children who have neuroblastoma that has come back or did not respond to prior treatment, aiming to see whether the treatment is safe and can shrink tumors.
Jinan, ShandongAges 1 year+ - NCT05126849RecruitingPhase 2
Stem cell transplant using half-matched donor and cyclophosphamide
This trial tests a stem cell transplant option for children or young adults with severe aplastic anemia that did not respond to prior immune-suppressing treatment. It uses a “half-matched” donor and gives post-transplant cyclophosphamide to help the donor cells work and reduce certain immune reactions.
AmiensAges 3–35 - NCT06086197RecruitingPhase 2
A drug combo for early relapsed or refractory DLBCL
This trial tests a combination of chemotherapy drugs for people with a type of lymphoma called diffuse large B-cell lymphoma that has either come back early or never fully responded to first treatment. The goal is to see if this drug combination can help control the lymphoma.
Hangzhou, ZhejiangAges 18 years+ - NCT07802717RecruitingPhase 1
CAR T cell therapy for returning multiple myeloma
This trial tests a new treatment called VV169, a type of CAR T cell therapy, for people with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if it is safe and if it can help fight the cancer.
Rochester, MinnesotaAges 18 years+ - NCT05546723RecruitingPhase 1
Study drug for multiple myeloma after several prior treatments
This Phase 1 trial tests LMY-920 in people with multiple myeloma that has returned or stopped responding after multiple standard therapies. It’s meant to see if the treatment can work and to better understand its safety and side effects in this situation.
Cleveland, OhioAges 18 years+ - NCT06732232RecruitingEarly Phase 1
CAR-T therapy for multiple myeloma that returned or didn't respond
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
ShanghaiAges 18–75 - NCT07502287RecruitingPhase 1/Phase 2
Dual-target CAR-NK cell therapy for children with neuroblastoma
This trial tests a new type of cell therapy (CAR-NK) that uses your child's own immune cells to attack two different markers on neuroblastoma tumors, called GD2 and B7-H3. It's for children with high-risk neuroblastoma that has come back or hasn't responded to standard treatments.
Shenzhen, GuangdongAges 1–21 - NCT07477912RecruitingPhase 1/Phase 2
BCMA-targeting CAR-T for relapsed/refractory multiple myeloma
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
MinskAges 18 years+ - NCT06751134RecruitingPhase 1
Engineered immune cells for relapsed neuroblastoma in children
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
Nanjing, JiangsuAges 1–12 - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Gilbert, ArizonaAges 18 years+ - NCT07369895RecruitingPhase 1
A new cell therapy for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07254754RecruitingPhase 2
CAR-T cell therapy for late-relapse aggressive lymphoma
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
A Coruña, A CoruñaAges 18 years+ - NCT07234110Recruiting
CD5 CAR-T therapy for returning blood cancers
This trial tests a new treatment using your own immune cells, modified to find and attack cancer cells that have a CD5 marker. It may be an option for people with certain lymphomas or leukemia that have not responded to standard treatments or have come back.
Tianjin, Tianjin MunicipalityAges 1–70 - NCT07126236RecruitingPhase 2
Epcoritamab for first relapse of large B-cell lymphoma
This trial tests a new drug called epcoritamab for people whose large B-cell lymphoma has come back after or didn't fully respond to their first treatment. It's an option for those who cannot or choose not to have CAR-T therapy or a stem cell transplant.
Seville, AndalusiaAges 18 years+ - NCT07087002RecruitingPhase 1
GPC2-CAR T cells for children and young adults with relapsed medulloblastoma
This trial tests a new type of cell therapy called GPC2-CAR T cells for children and young adults whose medulloblastoma or related brain tumor has come back or not responded to standard treatment. The goal is to see if these specially designed immune cells can find and attack the tumor.
Palo Alto, CaliforniaAges 1–30 - NCT07081646RecruitingPhase 1/Phase 2
CAR T cell therapy for AL amyloidosis
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
Phoenix, ArizonaAges 18 years+ - NCT07058103RecruitingPhase 2
Combination therapy for relapsed or refractory angioimmunoblastic T-cell lymphoma
This trial tests a combination of five drugs (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for patients with angioimmunoblastic T-cell lymphoma (AITL) that has come back or not responded to previous treatment. The goal is to see if this combination can shrink tumors or stop the disease from growing.
Xuzhou, JiangsuAges 18 years+
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory peripheral t cell lymphoma?
- Yes. Clin2 currently lists 1,697 recruiting relapsed or refractory peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.